The ILDR1 gene deafness autosomal recessive type 42 genetic test is a specialized diagnostic tool used to identify mutations in the ILDR1 gene, which are linked to a form of genetic hearing loss known as autosomal recessive nonsyndromic deafness 42 (DFNB42). This condition is characterized by the absence of other clinical symptoms beyond hearing impairment, making genetic testing crucial for accurate diagnosis. The test is conducted through a comprehensive analysis of the patient's DNA to detect specific genetic alterations associated with DFNB42, providing essential information for early intervention and management strategies for affected individuals and their families.
Performed at DNA Labs UAE, a leading facility in genetic diagnostics, the test ensures high accuracy and reliability in results. The cost of the ILDR1 gene deafness autosomal recessive type 42 genetic test is set at 4400 AED, reflecting the intricate processes and sophisticated technology employed in identifying the genetic markers associated with this condition. Opting for this test at DNA Labs UAE not only offers a pathway to understanding the genetic basis of hearing loss in patients but also supports families in making informed decisions regarding health and future planning.
The "CIB2 Gene Deafness Autosomal Recessive Type 48 Genetic Test" is a specialized diagnostic tool available at DNA Labs UAE, aimed at detecting mutations in the CIB2 gene, which are linked to a form of hereditary hearing loss known as Autosomal Recessive Deafness Type 48 (DFNB48). This condition is characterized by a genetic predisposition to early-onset sensorineural hearing impairment, which means it affects the nerve pathways from the inner ear to the brain. The test is crucial for families with a history of this condition, offering them the chance to understand their genetic status and make informed decisions about future healthcare and family planning. The cost of the test is set at 4400 AED, reflecting the specialized nature of the genetic analysis and the invaluable insights it provides to affected individuals and their families. Conducted in the state-of-the-art facilities of DNA Labs UAE, this genetic test stands as a beacon of hope for many seeking clarity on their genetic predisposition to hearing loss.
The MARVELD2 gene plays a crucial role in hearing processes, and mutations in this gene can lead to deafness autosomal recessive type 49 (DFNB49), a form of hereditary hearing loss. This condition is characterized by the absence or severe impairment of hearing from birth. Genetic testing for DFNB49 is essential for early diagnosis, which can significantly benefit from early interventions and management strategies for affected individuals.
DNA Labs UAE offers a specialized genetic test to detect mutations in the MARVELD2 gene associated with deafness autosomal recessive type 49. The test involves analyzing the individual's DNA to identify any genetic alterations that could lead to this specific type of hearing loss. This precise genetic testing is crucial for families with a history of hearing loss, providing them with valuable information regarding the risk and inheritance patterns of this condition.
The cost of the MARVELD2 gene deafness autosomal recessive type 49 genetic test at DNA Labs UAE is 4400 AED. This investment covers the comprehensive analysis required to identify the genetic mutations responsible for this condition, offering families and individuals critical insights into managing and potentially mitigating the impacts of hereditary hearing loss.
The CCDC50 Gene Deafness Autosomal Dominant Type 44 Genetic Test is a specialized diagnostic procedure designed to identify mutations in the CCDC50 gene, which are associated with Autosomal Dominant Non-Syndromic Hearing Loss (ADNSHL), specifically classified as Type 44. This condition is characterized by varying degrees of hearing impairment that can be present from birth or develop later in life, passed down through families in an autosomal dominant pattern. This means that just one copy of the altered gene in each cell is sufficient to cause the disorder.
The test is conducted at DNA Labs UAE, a reputable facility known for its advanced genetic testing services. By analyzing a patient's DNA, the test can confirm a diagnosis of this type of hearing loss, predict its progression, and inform decisions regarding management and treatment. It is particularly useful for families with a history of hearing loss, providing crucial information for future planning and support.
The cost of the CCDC50 Gene Deafness Autosomal Dominant Type 44 Genetic Test at DNA Labs UAE is 4400 AED. This investment covers the technical process of isolating and examining the patient's DNA for the specific genetic mutations associated with the condition. Given the complex nature of genetic testing and the specialized knowledge required to interpret the results, the cost reflects both the technical and professional expertise provided by the laboratory. Patients considering this test are encouraged to discuss it with their healthcare provider to understand its benefits and implications fully.
The MYO1A Gene Deafness Autosomal Dominant Type 48 Genetic Test is a specialized diagnostic tool designed to identify mutations in the MYO1A gene, which are linked to Autosomal Dominant Non-Syndromic Hearing Loss (ADNSHL), specifically categorized as Type 48. This form of hearing loss is characterized by its genetic inheritance pattern, where a single copy of the altered gene in each cell is sufficient to cause the disorder. The MYO1A gene plays a crucial role in the development and maintenance of the inner ear's structure, which is essential for proper hearing.
Conducted at DNA Labs UAE, this test aims to provide individuals and families with critical genetic information that can help in understanding the risk of developing this type of hearing loss or passing it on to future generations. Early detection through this genetic test can facilitate timely interventions and support measures to manage the condition effectively.
The cost of the MYO1A Gene Deafness Autosomal Dominant Type 48 Genetic Test is set at 4400 AED. This investment covers the comprehensive analysis required to detect mutations in the MYO1A gene, offering a valuable resource for affected individuals and their healthcare providers in devising personalized management plans and making informed decisions about their health and well-being.
The CEACAM16 Gene Deafness Autosomal Dominant Type 4B Genetic Test is a specialized diagnostic tool designed to identify mutations in the CEACAM16 gene, which are associated with Autosomal Dominant Non-Syndromic Hearing Loss (ADNSHL) type 4B. This condition is characterized by varying degrees of hearing impairment that can be passed down through families. The test is particularly crucial for individuals with a family history of hearing loss, as early detection can aid in timely intervention and management strategies to improve quality of life.
Performed at DNA Labs UAE, a leading facility in genetic testing, the process involves collecting a DNA sample, typically through a blood draw or a cheek swab, which is then analyzed for specific genetic alterations in the CEACAM16 gene. The presence of these mutations can confirm the diagnosis of Autosomal Dominant Type 4B hearing loss, enabling healthcare providers to offer personalized care and counseling for affected individuals and their families.
The cost of the CEACAM16 Gene Deafness Autosomal Dominant Type 4B Genetic Test at DNA Labs UAE is 4400 AED. This investment covers the comprehensive analysis and the detailed report provided by the lab, which includes actionable insights for managing the condition. It is a crucial step for those at risk, offering them an opportunity to understand their genetic makeup and take proactive measures towards hearing health.
The GSDME Gene Deafness Autosomal Dominant Type 5 Genetic Test is a specialized diagnostic procedure offered at DNA Labs UAE, designed to identify mutations in the GSDME gene that are associated with Autosomal Dominant Deafness Type 5 (DFNA5). This form of hearing loss is characterized by its genetic inheritance pattern, where a single copy of the mutated gene from an affected parent can lead to the condition in the offspring. The test plays a crucial role in the early detection and management of this type of hearing impairment, facilitating informed decisions regarding treatment options and preventive measures for at-risk family members. Priced at 4400 AED, this genetic test involves analyzing the individual's DNA to detect specific mutations in the GSDME gene, providing a comprehensive understanding of the genetic basis of their condition. By opting for this test at DNA Labs UAE, patients can expect accurate results, professional consultation, and guidance on the implications of their genetic profile in relation to Autosomal Dominant Deafness Type 5.
The POU4F3 gene plays a crucial role in the development and maintenance of hair cells in the inner ear, which are essential for hearing. Mutations in this gene can lead to autosomal dominant deafness type 52 (DFNA52), a form of progressive hearing loss that usually begins in adulthood. To diagnose this condition, individuals suspected of having DFNA52 can undergo genetic testing specifically targeting the POU4F3 gene.
DNA Labs UAE offers a specialized genetic test for identifying mutations in the POU4F3 gene associated with autosomal dominant deafness type 52. The test is comprehensive and designed to provide accurate results, aiding in the diagnosis and potential management of this hearing loss condition. The cost of the test is 4400 AED, reflecting the intricate processes and advanced technology involved in identifying the genetic mutation responsible for the condition. Undergoing this test at DNA Labs UAE ensures access to expert analysis and interpretation of the results, which can be crucial for affected individuals and their families in understanding the condition and exploring possible interventions or therapies.
The WFS1 gene, associated with Wolfram syndrome, plays a critical role in the inner ear's function, impacting hearing capabilities. Mutations in the WFS1 gene can lead to autosomal dominant nonsyndromic hearing loss, specifically classified as Deafness Autosomal Dominant Type 6 (DFNA6). This condition is characterized by progressive, sensorineural hearing loss, primarily affecting the high frequencies.
To diagnose this specific genetic cause of hearing loss, a genetic test targeting the WFS1 gene can be conducted. DNA Labs UAE offers this specialized testing service. The test involves collecting a DNA sample, usually through a blood draw or a cheek swab, which is then analyzed for mutations in the WFS1 gene that are known to cause DFNA6.
The cost of the WFS1 Gene Deafness Autosomal Dominant Type 6 Genetic Test at DNA Labs UAE is 4400 AED. This test is crucial for individuals with a family history of hearing loss or those experiencing symptoms of hearing impairment, as it can provide a definitive diagnosis, inform about the progression of the condition, and guide management and treatment options. Additionally, the results can have implications for family planning for those affected or at risk.
The "DIABLO Gene Deafness Autosomal Dominant Type 64 Genetic Test" is a specialized genetic screening designed to identify mutations in the DIABLO gene, which are linked to Autosomal Dominant Non-Syndromic Hearing Loss (ADNSHL) Type 64. This condition is characterized by varying degrees of hearing impairment that can be passed down through families. The test is a crucial tool for individuals with a family history of hearing loss, enabling early diagnosis and intervention strategies to manage the condition effectively.
Performed at DNA Labs UAE, a reputable facility known for its advanced genetic testing services, the test ensures accuracy and reliability in results. The cost of the test is set at 4400 AED, reflecting the intricate processes and sophisticated technology employed in detecting the specific genetic alterations responsible for this type of deafness. By opting for this test, individuals gain valuable insights into their genetic predisposition to hearing loss, empowering them with the knowledge to make informed decisions regarding their health and lifestyle.
